Calendar of Events

February 9-10, 1990
The 8th Annual UC Davis Infectious Disease Conference, "Practical Review and Update of Infectious Disease," will be held at the Hilton Inn in Sacramento, California. The conference will provide a review and update of practical information for internists, family physicians, pharmacists and other healthcare professionals involved in the management of patients with infectious diseases. Some of the areas to be covered are: Lyme Disease, AIDS, recommendations for travelers, antibiotic pharmacokinetics and new lab techniques for identifying infections. Eleven hours of Category I AMA/CMA/AAFP and 11 hours of Pharmacist/Credit (applied for) will be available. The cost is $165 for physicians and $105 for all others. Sponsors are the Office of Continuing Medical Education, the Department of Internal Medicine and the Department of Family Practice. For further information contact Nina Musselman, Office of Continuing Medical Education, UC Davis School of Medicine, 2701 Stockton Blvd., Sacramento, CA 95817. Telephone (916) 453-5390.

February 23-24, 1990
The "Fourth Infectious Diseases Symposium" will be held in El Paso, Texas. Sponsored by the Providence Memorial Hospital, the symposium is a national conference devoted to the scientific and practical aspects of diagnosis, management and control of infectious diseases. Fees for this symposium are $150 for physicians and $75 for nurses, pharmacists, allied healthcare workers, residents, interns and students with current registration. For more information, contact Karen Greenup, Providence Memorial Hospital, 2001 N. Oregon St., El Paso, TX 79902. Telephone (915) 542-6660.

March 6, 1990
The third annual "Infection Control Product Exhibition of New England" will be held at the Sheraton Sturbridge Conference Center, Sturbridge, Massachusetts. Sponsored by Infection Control Consultants of America and the Association for Practitioners in Infection Control-New England Chapter, the Exhibition features opportunities for healthcare professionals to compare infection control products, obtain literature and sample and discuss needs and concerns with sales representatives. Fees for this exhibition are $5 for participants and $350 for exhibitors. For more information, contact Infection Control Consultants of America, P.O. Box 5242, Turnpike Station, Shrewsbury, MA 01545. Telephone (508) 443-0176.

March 26-28, 1990
"Infection Control Update-1990" will be held at the Marriott Hotel, Salt Lake City, Utah. The conference is sponsored by the Rocky Mountain Infection Control Association. Topics will be of interest to infection control practitioners and hospital epidemiologists. For more information, contact Barbara Mooney, RN, BSN, CIC, Nurse Epidemiologist, University of Utah Hospital, Salt Lake City, UT 84132. Telephone (801) 581-2706.

March 26-April 9, 1990
An extension training program for beginning infection control and quality assurance practitioners will be held at the University of Iowa Hospitals and Clinics in Iowa City, Iowa. The program is sponsored by the University of Iowa Program of Epidemiology and Quality Assurance Support Service. For more information contact Jeanne Lyons, RN, BS, CIC, Nurse Epidemiologist, University of Iowa Hospitals and Clinics, C41 General Hospital, Iowa City, IA 52242. Telephone (319) 356-1606.

March 30, 1990
The 7th Annual Infectious Disease Symposium will be held at the Santa Barbara Miramar Resort and Conference Center, Santa Barbara, California. The sponsor of the event is APIC Camino Real. Seven contact hours credit are available for nurses who attend. For further symposium information contact Patsy Favalora, RN, BS, CIC, Infection Control Coordinator, Cottage Hospital, P.O. Box 689, Santa Barbara, CA 93102. Telephone (805) 569-7204.

June 6-8, 1990
"Sailing Into the 90's," a conference sponsored by the Community and Hospital Infection Control Association of Canada, will be held in Kingston, Ontario, Canada at the Ambassador Motor Hotel. For information contact June Gorrell, Registration Chair, Trenton Memorial Hospital, Trenton, Ontario, Canada, K8V 5S6.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY publishes Calendar of Events as a service to its readers **as space permits.** *Notices of symposia, workshops, and other educational offerings should contain a mailing address and telephone number of a contact person and must be submitted at least three months* **before publication.** *Send typewritten notices to* Managing *Editor, IC & HE Editorial Offices, C41 GH, University of Iowa Hospitals and Clinics,* Iowa *City, IA 52242.*

https://doi.org/10.1086/645956 Published online by Cambridge University Press

PARENTERAL POWER IN ORAL FORM: THE POWER TO ERADICATE.*



(ciprofloxacin HCl/Miles)

* Achieves 95% favorable clinical response (resolution + improvement) of infections due to susceptible strains of indicated pathogens. See indicated organisms in prescribing information.

https://doi.org/10.1086/645956

THE POWER TO ERADICATE* IN LOWER RESPIRATORY INFECTIONS.

Power that achieves **96%** favorable results in lower respiratory infections.[1*†]

Power that destroys pneumopathogens in vitro that are not covered by cefaclor, cephalexin, or ampicillin.[2-4*]

Power that demonstrates significant activity even against organisms resistant to other agents such as *H. influenzae* and the Enterobacteriaceae.[1,5-7*]

Power that's well tolerated and is comparable in cost with cefaclor and amoxicillin/clavulanate potassium.[8]

NOTES: Concurrent administration of ciprofloxacin with theophylline may lead to elevated plasma concentrations of theophylline and prolongation of its elimination half-life. This may result in increased risk of theophylline-related adverse reactions. If concomitant use cannot be avoided, plasma levels of theophylline should be monitored and dosage adjustments made as appropriate.

Antacids containing magnesium hydroxide or aluminum hydroxide interfere with the absorption of ciprofloxacin, resulting in serum and urine levels lower than desired; concurrent administration of these agents with ciprofloxacin should be avoided.

A history of hypersensitivity to ciprofloxacin is a contraindication to its use.

A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

CIPRO® SHOULD NOT BE USED IN CHILDREN, ADOLESCENTS, OR PREGNANT WOMEN.


The eradicator.*



(ciprofloxacin HCl/Miles)

* Achieves 96% favorable clinical response (resolution + improvement) of infections due to susceptible strains of indicated pathogens. See indicated organisms in prescribing information.

https://doi.org/10.1086/645956 Published online by Cambridge University Press



† Clinical response includes "resolution" plus "improvement" data derived from a pool of studies conducted by investigators who may have used different criteria to define clinical response.

See following page for brief summary of prescribing information.

https://doi.org/10.1086/645956 Published online by Cambridge University Press

Cipro® TABLETS

(ciprofloxacin HCl/Miles)

THE POWER TO ERADICATE* IN LOWER RESPIRATORY INFECTIONS.

CIPRO® TABLETS
(ciprofloxacin HCl/Miles)

BRIEF SUMMARY
CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

INDICATIONS AND USAGE

Cipro® is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:

Lower Respiratory Infections caused by *Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae,* and *Streptococcus pneumoniae.*

Skin and Skin Structure Infections caused by *Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis,* and *Streptococcus pyogenes.*

Bone and Joint Infections caused by *Enterobacter cloacae, Serratia marcescens,* and *Pseudomonas aeruginosa.*

Urinary Tract Infections caused by *Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus epidermidis,* and *Streptococcus faecalis.*

Infectious Diarrhea caused by *Escherichia coli* (enterotoxigenic strains), *Campylobacter jejuni, Shigella flexneri,*[1] and *Shigella sonnei*[1] when antibacterial therapy is indicated.

[1]*Efficacy for this organism in this organ system was studied in fewer than 10 infections.*

CONTRAINDICATIONS

A history of hypersensitivity to ciprofloxacin is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

WARNINGS

CIPROFLOXACIN SHOULD NOT BE USED IN CHILDREN, ADOLESCENTS, OR PREGNANT WOMEN. The oral administration of ciprofloxacin caused lameness in immature dogs. Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage. Related drugs such as nalidixic acid, cinoxacin, and norfloxacin also produced erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species (SEE ANIMAL PHARMACOLOGY SECTION IN FULL PRESCRIBING INFORMATION).

PRECAUTIONS

General: As with other quinolones, ciprofloxacin may cause central nervous system (CNS) stimulation, which may lead to tremor, restlessness, lightheadedness, confusion, and rarely to hallucinations or convulsive seizures. Therefore, ciprofloxacin should be used with caution in patients with known or suspected CNS disorders, such as severe cerebral arteriosclerosis or epilepsy, or other factors which predispose to seizures (SEE ADVERSE REACTIONS).

Anaphylactic reactions following the first dose have been reported in patients receiving therapy with quinolones. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reaction. Anaphylactic reactions may require epinephrine and other emergency measures. Ciprofloxacin should be discontinued at the first sign of hypersensitivity or allergy.

Severe hypersensitivity reactions characterized by rash, fever, eosinophilia, jaundice, and hepatic necrosis with *fatal outcome have been reported rarely (less than one per million prescriptions) in patients receiving ciprofloxacin* along with other drugs. The possibility that these reactions were related to ciprofloxacin cannot be excluded. Ciprofloxacin should be discontinued at the first appearance of a skin rash or any sign of other hypersensitivity reaction.

Crystals of ciprofloxacin have been observed rarely in the urine of human subjects but more frequently in the urine of laboratory animals (SEE ANIMAL PHARMACOLOGY SECTION IN FULL PRESCRIBING INFORMATION). Crystalluria related to ciprofloxacin has been reported only rarely in man, because human urine is usually acidic. Patients receiving ciprofloxacin should be well hydrated, and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded.

Alteration of the dosage regimen is necessary for patients with impairment of renal function (SEE DOSAGE AND ADMINISTRATION).

As with any potent drug, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy.

Drug Interactions: As with other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated plasma concentrations of theophylline and prolongation of its elimination half-life. This may result in increased risk of theophylline-related adverse reactions. If concomitant use cannot be avoided, plasma levels of theophylline should be monitored and dosage adjustments made as appropriate.

Quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.

Antacids containing magnesium hydroxide or aluminum hydroxide may interfere with the absorption of ciprofloxacin resulting in serum and urine levels lower than desired; concurrent administration of these agents with ciprofloxacin should be avoided.

Concomitant administration of the nonsteroidal anti-inflammatory drug fenbufen with a quinolone has been reported to increase the risk of CNS stimulation and convulsive seizures.

Probenecid interferes with the renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in the serum. This should be considered if patients are receiving both drugs concomitantly.

As with other broad-spectrum antibiotics, prolonged use of ciprofloxacin may result in overgrowth of nonsusceptible organisms. *Repeated evaluation of the patient's condition and microbial susceptibility testing is essential.* If superinfection occurs during therapy, appropriate measures should be taken.

Information for Patients: Patients should be advised that ciprofloxacin may be taken with or without meals. The preferred time of dosing is two hours after a meal. Patients should also be advised to drink fluids liberally and not take antacids containing magnesium or aluminum.

Patients should be advised that ciprofloxacin may be associated with hypersensitivity reactions, even following a single dose, and to discontinue the drug at the first sign of a skin rash or other allergic reaction.

Ciprofloxacin may cause dizziness or lightheadedness; therefore patients should know how they react to this drug before they operate an automobile or machinery or engage in activities requiring mental alertness or coordination.

Patients should be advised that ciprofloxacin may increase the effects of theophylline and caffeine.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Eight in vitro mutagenicity tests have been conducted with ciprofloxacin and the test results are listed below:

- Salmonella/Microsome Test (Negative)
- *E. coli* DNA Repair Assay (Negative)
- Mouse Lymphoma Cell Forward Mutation Assay (Positive)
- Chinese Hamster V_{79} Cell HGPRT Test (Negative)
- *Syrian Hamster Embryo Cell Transformation Assay (Negative)*
- *Saccharomyces cerevisiae* Point Mutation Assay (Negative)
- *Saccharomyces cerevisiae* Mitotic Crossover and Gene Conversion Assay (Negative)
- Rat Hepatocyte DNA Repair Assay (Positive)

Thus, two of the eight tests were positive, but the results of the following three in vivo test systems gave negative results:

- Rat Hepatocyte DNA Repair Assay
- Micronucleus Test (Mice)
- Dominant Lethal Test (Mice)

Long-term carcinogenicity studies in rats and mice have been completed. After daily oral dosing for up to 2 years there is no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.

Pregnancy—Pregnancy Category C. Reproduction studies have been performed in rats and mice at doses up to 6 times the usual daily human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ciprofloxacin. In rabbits, as with most antimicrobial agents, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in maternal weight loss and an increased incidence of abortion. No teratogenicity was observed at either dose. After intravenous administration, all doses up to 20 mg/kg, no maternal toxicity was produced, *and no embryotoxicity or teratogenicity was observed. There are, however, no adequate and well-*controlled studies in pregnant women. SINCE CIPROFLOXACIN, LIKE OTHER DRUGS IN ITS CLASS, CAUSES ARTHROPATHY IN IMMATURE ANIMALS, IT SHOULD NOT BE USED IN PREGNANT WOMEN (SEE WARNINGS).

Nursing Mothers: It is not known whether ciprofloxacin is excreted in human milk. However, it is known that ciprofloxacin is excreted in the milk of lactating rats and that other drugs of this class are excreted in human milk. Because of this and because of the potential for serious adverse reactions from ciprofloxacin in nursing infants, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Patients under the age of 18 were not included in the clinical trials of ciprofloxacin because ciprofloxacin as well as other quinolones causes arthropathy in immature animals. Ciprofloxacin should not be used in children or adolescents (SEE WARNINGS).

ADVERSE REACTIONS

Ciprofloxacin is generally well tolerated. During clinical investigation, 2,799 patients received 2,868 courses of the drug. Adverse events that were considered likely to be drug related occurred in 7.3% of courses, possibly related in 9.2%, and remotely related in 3.0%. Ciprofloxacin was discontinued because of an adverse event in 3.5% of courses, primarily involving the gastrointestinal system (1.5%), skin (0.6%), and central nervous system (0.4%). Those events typical of quinolones are italicized.

The most frequently reported events, drug related or not, were *nausea* (5.2%), *diarrhea* (2.3%), *vomiting* (2.0%), *abdominal pain/discomfort* (1.7%), *headache* (1.2%), *restlessness* (1.1%), and *rash* (1.1%).

Additional events that occurred in less than 1% of ciprofloxacin courses are listed below:

GASTROINTESTINAL: *(See above),* painful oral mucosa, oral candidiasis, dysphagia, intestinal perforation, gastrointestinal bleeding.

CENTRAL NERVOUS SYSTEM: *(See above), dizziness, lightheadedness, insomnia, nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression, paresthesia.*

SKIN/HYPERSENSITIVITY: *(See above), pruritus, urticaria, photosensitivity, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands,* cutaneous candidiasis, hyperpigmentation, erythema nodosum.

Allergic reactions ranging from urticaria to anaphylactic reactions have been reported (SEE PRECAUTIONS).

SPECIAL SENSES: *blurred vision, disturbed vision (change in color perception, overbrightness of lights), decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste.*

MUSCULOSKELETAL: *joint or back pain, joint stiffness,* aching, neck or chest pain, flare-up of gout.

RENAL/UROGENITAL: *interstitial nephritis, nephritis, renal failure,* polyuria, *urinary retention,* urethral bleeding, vaginitis, acidosis.

CARDIOVASCULAR: palpitations, atrial flutter, ventricular ectopy, syncope, hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis.

RESPIRATORY: epistaxis, laryngeal or pulmonary edema, hiccough, hemoptysis, dyspnea, bronchospasm, pulmonary embolism.

Most of the adverse events reported were described as only mild or moderate in severity, abated soon after the drug was discontinued, and required no treatment.

In several instances, nausea, vomiting, tremor, restlessness, agitation, or palpitations were judged by investigators to be related to elevated plasma levels of theophylline possibly as a result of a drug interaction with ciprofloxacin.

Other adverse events reported in the postmarketing phase include anaphylactoid reactions, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, hepatic necrosis, postural hypotension, possible exacerbation of myasthenia gravis, confusion, dysphasia, nystagmus, pseudomembranous colitis, dyspepsia, flatulence, and constipation. Also reported were agranulocytosis; elevation of serum triglycerides, serum cholesterol, blood glucose, serum potassium; prolongation of prothrombin time; albuminuria; candiduria, vaginal candidiasis; and renal calculi (SEE PRECAUTIONS).

Adverse Laboratory Changes: Changes in laboratory parameters listed as adverse events without regard to drug relationship:

Hepatic—Elevations of: ALT (SGPT) (1.9%), AST (SGOT) (1.7%), alkaline phosphatase (0.8%), LDH (0.4%), serum bilirubin (0.3%).

Cholestatic jaundice has been reported.

Hematologic—Eosinophilia (0.6%), leukopenia (0.4%), decreased blood platelets (0.1%), elevated blood platelets (0.1%), pancytopenia (0.1%).

Renal—Elevations of: Serum creatinine (1.1%), BUN (0.9%).

CRYSTALLURIA, CYLINDRURIA, AND HEMATURIA HAVE BEEN REPORTED.

Other changes occurring in less than 0.1% of courses were: *Elevation of serum gammaglutamyl transferase, elevation of serum amylase, reduction in blood glucose, elevated uric acid, decrease in hemoglobin, anemia,* bleeding diathesis, increase in blood monocytes, and leukocytosis.

OVERDOSAGE

Information on overdosage in humans is not available. In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed and given supportive treatment. Adequate hydration must be maintained. Only a small amount of ciprofloxacin (~ 10%) is removed from the body after hemodialysis or peritoneal dialysis.

DOSAGE AND ADMINISTRATION

The usual adult dosage for patients with urinary tract infections is 250 mg every 12 hours. For patients with complicated infections caused by organisms not highly susceptible, 500 mg may be administered every 12 hours.

Lower respiratory tract infections, skin and skin structure infections, and bone and joint infections may be treated with 500 mg every 12 hours. For more severe or complicated infections, a dosage of 750 mg may be given every 12 hours.

The recommended dosage for infectious diarrhea is 500 mg every 12 hours.

In patients with renal impairment, some modification of dosage is recommended (SEE DOSAGE AND ADMINISTRATION SECTION IN FULL PRESCRIBING INFORMATION).

HOW SUPPLIED

Cipro® (ciprofloxacin HCl/Miles) is available as tablets of 250 mg, 500 mg, and 750 mg in bottles of 50, and in Unit-Dose packages of 100 (SEE FULL PRESCRIBING INFORMATION FOR COMPLETE DESCRIPTION).

References: 1. Data on file, Miles Inc, Pharmaceutical Division. **2.** *Physicians' Desk Reference®.* 43rd ed. Oradell, NJ: Medical Economics Co Inc; 1989:891, 1168, 1441, 2098. **3.** Wollschlager CM, et al. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. *Am J Med.* 1987;82(suppl 4A):164-168. **4.** Feist H, et al. Comparative study of ciprofloxacin and cefalexin in the treatment of patients with lower respiratory tract infections. In: Neu HC, Weuta H, eds. *1st International Ciprofloxacin Workshop.* Amsterdam: Excerpta Medica; 1986:265-267. **5.** Parry MF. Quinolone resistance—trends in U.S. susceptibility data. In: *Ciprofloxacin: Major Advances In Intravenous and Oral Quinolone Therapy, Scientific Program and Abstracts.* Naples, Florida: 1989:21. **6.** Sanders CC, et al. Overview of preclinical studies with ciprofloxacin. *Am J Med.* 82(suppl 4A):2-11. **7.** Machka K, et al. In vitro activity of new antibiotics against *Haemophilus influenzae. Eur J Clin Microbiol Infect Dis.* 1988;7:812-814. **8.** *Redbook Update.* 1989;8(5):4,6,7.

***Achieves 96% favorable clinical response (resolution + improvement) of infections due to susceptible strains of indicated pathogens. See indicated organisms in prescribing information.**

For further information, contact the Miles Information Service: 1-800-642-4776. In VA, call collect: 703-391-7888.

COMMITTED TO THERAPEUTIC EFFICIENCY

MILES

Miles Inc.
Pharmaceutical Division
400 Morgan Lane
West Haven, CT 06516

© September 1989 Miles Inc., Pharmaceutical Division

CO9299 MIL-6033

https://doi.org/10.1086/645956 Published online by Cambridge University Press